Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX01 Ointment 1% in Japanese adults with actinic keratosis
NCT05231044Phase 3Completed
- Sponsor
- PharmaEssentia
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tirbanibulin in actinic keratosis (AK), sponsored by PharmaEssentia. Started Dec 2021; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05231044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231044.